DermatologyNews.net

Dermatology Xagena

XagenaNewsletter
Medical Meeting
Xagena Mappa
Neurobase.it

Search results for "Secukinumab"

The results from the head-to-head phase III FIXTURE study showing Secukinumab ( AIN457 ), an interleukin-17A ( IL-17A ) inhibitor, was significantly superior to Etanercept ( Enbrel ) in moderate-to-se ...


The Dermatologic and Ophthalmic Drugs Advisory Committee ( DODAC ) to the US Food and Drug Administration ( FDA ) has voted unanimously to support the approval of AIN457 ( Secukinumab ), a selective i ...


Results from two pivotal phase III studies evaluating the interleukin-17A ( IL-17A ) inhibitor Secukinumab ( AIN457 ) were published in the New England Journal of Medicine ( NEJM ). Secukinumab met ...


The phase IIIb CLEAR study for Secukinumab ( Cosentyx ) has demonstrated superiority to Ustekinumab ( Stelara ) and met its primary endpoint of achieving PASI 90, which represents clear or almost clea ...


New data demonstrating that Cosentyx ( Secukinumab ) provides high levels of skin clearance and sustained efficacy in patients with moderate-to-severe plaque psoriasis while maintaining a favorable sa ...


Nail psoriasis is associated with functional impairment, pain and reduced quality of life. The aim of a study was to demonstrate the superiority of Secukinumab ( Cosentyx ) versus placebo in cleari ...


ECLIPSE trial has demonstrated that Guselkumab ( Tremfya ) was superior to Secukinumab ( Cosentyx ) in treating adults with moderate to severe plaque psoriasis for the primary endpoint assessed at wee ...